Screener
Neurocrine Biosciences NBIX Balance Sheet Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $332.4M+22.2% | $274.5M+35.8% | $721M+199% | $348.2M-2.5% | $272M+84.2% | ||
| $57.4M-91.9% | $1.05B+40.1% | $767.4M-9.0% | $774.6M-11.9% | $711.6M-20.9% | ||
| $1.64B-6.4% | $2.44B+48.7% | $2.52B+46.3% | $2.16B+15.0% | $1.75B+4.7% | ||
| $90.5M-1.3% | $90.9M+4.5% | $89.8M+8.7% | $97.3M+21.6% | $91.7M+14.5% | ||
| $5.36B+37.8% | $4.91B+33.0% | $4.63B+24.5% | $4.27B+20.7% | $3.89B+17.7% | ||
| $808.3M+65.1% | $773M+62.7% | $674.3M+46.1% | $584.3M+48.8% | $489.5M+36.5% | ||
| $874.5M+60.1% | $831.7M+59.1% | $743.4M+46.4% | $638M+48.5% | $546.3M+37.1% | ||
| $1.67B+39.3% | $1.5B+30.1% | $1.38B+22.1% | $1.26B+54.7% | $1.2B+50.2% | ||
| 100K-100.0% | 220M0.0% | 220M+219,900% | 220M0.0% | 220M0.0% | ||
| $724M+757% | $589.6M+11,225% | $447.7M+1,433% | $294M+263% | $84.5M+274% | ||
| $3.69B+37.1% | $3.41B+34.4% | $3.25B+25.6% | $3B+10.5% | $2.69B+7.4% | ||
| $5.36B+37.8% | $4.91B+33.0% | $4.63B+24.5% | $4.27B+20.7% | $3.89B+17.7% |
FAQ
- What are Neurocrine Biosciences's total assets?
- Neurocrine Biosciences (NBIX) holds $5.4B in total assets, up 37.8% year over year.
- How much debt does Neurocrine Biosciences have?
- Neurocrine Biosciences carries $461.6M in total debt against $3.7B of shareholders' equity, a debt-to-equity ratio of 0.13.
- How much cash does Neurocrine Biosciences have?
- Neurocrine Biosciences holds $332.4M in cash and equivalents.
- Can Neurocrine Biosciences cover its short-term obligations?
- Its current ratio is 1.87 — current assets exceed current liabilities.
- Where does Neurocrine Biosciences's balance sheet data come from?
- Every line is extracted from Neurocrine Biosciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
